Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER

Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens r...

Full description

Saved in:
Bibliographic Details
Published in:Patient preference and adherence 2009-01, Vol.2, p.233-240
Main Authors: Birnbaum, Michael, Sharif, Zafar
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 240
container_issue
container_start_page 233
container_title Patient preference and adherence
container_volume 2
creator Birnbaum, Michael
Sharif, Zafar
description Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_21461064</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21461064</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_214610643</originalsourceid><addsrcrecordid>eNqNzL0KwjAUBeAgCNafd7iTm9DY0lZXqbi4iIObhPTWXolJ7E0FfXoz-ABOBw7fOSORSFmWq6raXCZiynxP0yIr1jIRtyM2pFUgZ0E1HfZoNQJZYN3Rx_kuFqS24CNBG8Bjzx51oBcyKNtA6BC0IRtPDAyBDIU3uDYODEVMjbMI9Wkuxq0yjItfzsRyX593h5Xv3XNADtcHsUZjlEU38HUt80KmRZ79Db8B2krs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21461064</pqid></control><display><type>article</type><title>Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis Open Access</source><source>Publicly Available Content Database</source><creator>Birnbaum, Michael ; Sharif, Zafar</creator><creatorcontrib>Birnbaum, Michael ; Sharif, Zafar</creatorcontrib><description>Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.</description><identifier>EISSN: 1177-889X</identifier><language>eng</language><ispartof>Patient preference and adherence, 2009-01, Vol.2, p.233-240</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,37013</link.rule.ids></links><search><creatorcontrib>Birnbaum, Michael</creatorcontrib><creatorcontrib>Sharif, Zafar</creatorcontrib><title>Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER</title><title>Patient preference and adherence</title><description>Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.</description><issn>1177-889X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNqNzL0KwjAUBeAgCNafd7iTm9DY0lZXqbi4iIObhPTWXolJ7E0FfXoz-ABOBw7fOSORSFmWq6raXCZiynxP0yIr1jIRtyM2pFUgZ0E1HfZoNQJZYN3Rx_kuFqS24CNBG8Bjzx51oBcyKNtA6BC0IRtPDAyBDIU3uDYODEVMjbMI9Wkuxq0yjItfzsRyX593h5Xv3XNADtcHsUZjlEU38HUt80KmRZ79Db8B2krs</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Birnbaum, Michael</creator><creator>Sharif, Zafar</creator><scope>7TK</scope></search><sort><creationdate>20090101</creationdate><title>Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER</title><author>Birnbaum, Michael ; Sharif, Zafar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_214610643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Birnbaum, Michael</creatorcontrib><creatorcontrib>Sharif, Zafar</creatorcontrib><collection>Neurosciences Abstracts</collection><jtitle>Patient preference and adherence</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Birnbaum, Michael</au><au>Sharif, Zafar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER</atitle><jtitle>Patient preference and adherence</jtitle><date>2009-01-01</date><risdate>2009</risdate><volume>2</volume><spage>233</spage><epage>240</epage><pages>233-240</pages><eissn>1177-889X</eissn><abstract>Antipsychotic medications provide the foundation for treatment of acute exacerbations as well as relapse prevention in patients with schizophrenia as demonstrated by rigorous placebo-controlled trials. However, despite their proven effectiveness, poor adherence to prescribed antipsychotic regimens remains the most important driver of suboptimal clinical outcomes in this population. This paper reviews the magnitude of the problem of medication non-adherence in patients with schizophrenia and the various factors that contribute to non-adherence, with particular emphasis on factors related to antipsychotic medications. The profile of the latest atypical antipsychotic, paliperidone extended-release (ER) tablets, is then reviewed and the implications of its unique pharmacokinetic profile for adherence in this patient population are discussed.</abstract></addata></record>
fulltext fulltext
identifier EISSN: 1177-889X
ispartof Patient preference and adherence, 2009-01, Vol.2, p.233-240
issn 1177-889X
language eng
recordid cdi_proquest_miscellaneous_21461064
source Open Access: PubMed Central; Taylor & Francis Open Access; Publicly Available Content Database
title Medication adherence in schizophrenia: patient perspectives and the clinical utility of paliperidone ER
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T00%3A53%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medication%20adherence%20in%20schizophrenia:%20patient%20perspectives%20and%20the%20clinical%20utility%20of%20paliperidone%20ER&rft.jtitle=Patient%20preference%20and%20adherence&rft.au=Birnbaum,%20Michael&rft.date=2009-01-01&rft.volume=2&rft.spage=233&rft.epage=240&rft.pages=233-240&rft.eissn=1177-889X&rft_id=info:doi/&rft_dat=%3Cproquest%3E21461064%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_214610643%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=21461064&rft_id=info:pmid/&rfr_iscdi=true